| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We investigated effect of androgen deprivation therapy (ADT) for prostate cancer (PC) on bladder cancer (BC) recurrence. We reviewed 20,328 patients with prostate cancer (PC) and identified 239 bladder cancer (BC). 162 patients made up the final cohort and 86 patients received ADT and 76 patients did not. 5-year recurrence-free survival (RFS) of BC was 40% in no-ADT patients and 76% in ADT patients. In multivariate analysis, ADT was an independent prognosticator for BC recurrence and its hazard ratio was 0.29. Since most of the ADT patients received luteinizing hormone-releasing hormone which deprives estrogens as well as androgens, we investigated expressions of androgen receptor (AR)/ estrogen receptor (ER)α/ERβ in ADT patients. Although AR expression significantly correlated with better RFS, ERα/ERβ expression showed no correlation with BC recurrence. These results suggest the preventive effect of ADT on BC recurrence is mediated by AR but not ERα/ERβ signal.
|
